Reform efforts can struggle because they focus on health systems at their strongest point rather than their weakest. Framing is a pernicious tool used to justify delays and denials. We argue that the uptake of GLP-1 therapies in the US is delivering remarkable results, and that we need to apply the lessons from that experience in Australia, challenging institutional narratives and reframing the public debate to focus on public health benefits.
 
		Latest Video
New Stories
- 
					
						The 'Dispatched' Week in Review Podcast - 31 OctoberOctober 31, 2025 - - Podcast
- 
					
						Aroa Biosurgery appoints Paul Shearer to Board as John Pinion retiresOctober 31, 2025 - - Australian Biotech
- 
					
						Immuron provides update on U.S. clinical trials for Travelan and IMM-529October 31, 2025 - - Australian Biotech
- 
					
						Firebrick Pharma launches new Nasodine Throat Spray for international marketsOctober 31, 2025 - - Australian Biotech
- 
					
						Amplia Therapeutics begins trading on U.S. OTCQB Venture MarketOctober 31, 2025 - - Australian Biotech
- 
					
						DHL Supply Chain opens New Zealand’s most advanced life sciences and healthcare logistics facilityOctober 31, 2025 - - Latest News
- 
					
						The continued 'false framing' aims to make us feel guilty for wanting more on healthOctober 31, 2025 - - Latest News
